PGEN Stock Analysis: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$3.81
-0.05 (-1.30%)
▼
5d:
-13.41%
30d:
-7.97%
90d:
+7.32%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.1/10
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called PGEN this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PGEN is down 13.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PGEN is down 13.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.05
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.38
13.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $3.81, which is considered oversold relative to its 30-day fair value range of $4.02 to $4.38. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.9) compared to its historical average (60.4). Remarkably, the market is currently pricing in an annual earnings decline of 32.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.69, while resistance sits at $4.68.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.45 (+226.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.69, while resistance sits at $4.68.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.45 (+226.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.02 -
$4.38
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding PGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 226.8% below Wall St target ($12.45)
- WARNING: Recommendation downgraded due to -13.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.02 -
$4.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.69
Resistance Level
$4.68
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.92
Wall Street Target
$12.45
(+226.8%)
Revenue Growth (YoY)
1633.9%
Valuation Discount vs History
-32.1% cheaper
PE vs Historical
18.9 vs 60.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-32.1%
(market-implied from PE analysis)
1-Year Target
$3.43
(-10%)
2-Year Target
$3.09
(-19%)
3-Year Target
$2.78
(-27%)
3-Yr Target (if PE normalizes)
(PE: 19→60)
$8.87
(+133%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.9 to 60.4
Stabilization Target:
$12.16
(+219.3%)
PE Expansion Potential:
+219.3%
Share & Embed Analysis
Last updated: June 04, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Randal J Kirk
SELL
4772781 shares
2026-03-30
Randal J Kirk
SELL
1900036 shares
2025-12-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 51 HOLD |
Advanced PGEN Option Strategies
Professional options setups generated by AI based on today's PGEN price and gamma walls.
